120
Participants
Start Date
January 31, 2012
Primary Completion Date
June 30, 2018
Study Completion Date
May 31, 2019
Vincristine, Irinotecan
"* D1 and D8: Vincristine 1.5 mg/m² (max 2mg) direct IV infusion (0.05 mg/kg for patient ≤ 10 kg)~* D1 to D5: Irinotecan 50 mg/m²/d, IV~ 1. cycle / 21 days"
Vincristine, Irinotecan, Temozolomide
"* D1 to D5: Temozolomide 125 mg/m²/d, PO (the dose will be escalated to 150 mg/m²/day at cycle 2 for patients who do not experience \> grade 3 toxicity of any kind)~* D1 and D8: Vincristine 1.5 mg/m² (maximum 2mg) direct IV infusion (0.05 mg/kg for patient ≤ 10 kg)~* D1 to D5: Irinotecan 50 mg/m²/d, IV~ 1. cycle / 21 days"
CHU d'Amiens Picardie Site Sud, Amiens
Hôpital des Enfants, Groupe Hospitalier Pellegrin, Bordeaux
Centre Oscar Lambret, Lille
Centre Léon Bérard, Lyon
CHU, Hôpital d'Enfants de la Timone, Marseille
Hôpital Arnaud de Villeneuve - CHU, Montpellier
CHU, Hôpital Mère enfants, Nantes
Hôpital Armand Trousseau, Paris
Institut Curie, Paris
Hôpital Jean Bernard, Poitiers
CHU Rennes - Hôpital Sud, Rennes
CHU St Etienne - Hôpital Nord, Saint-Etienne
Hôpital des enfants, Toulouse
CHRU, Tours
CHRU Hôpital d'Enfants, Vandœuvre-lès-Nancy
Institut Gustave Roussy, Villejuif
SFCE
UNKNOWN
Centre Oscar Lambret
OTHER